<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcimmunol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Immunology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcimmunol/</link>
        <description>The latest research articles published by BMC Immunology</description>
        <dc:date>2009-06-25T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/37" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/36" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/35" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/34" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/33" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/32" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/31" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/30" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/29" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/28" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/37">
        <title>Conserved cryptic recombination signals in Vkappa gene segments are cleaved in small pre-B cells</title>
        <description>Background:
The cleavage of recombination signals (RS) at the boundaries of immunoglobulin V, D, and J gene segments initiates the somatic generation of the antigen receptor genes expressed by B lymphocytes.  RS contain a conserved heptamer and nonamer motif separated by non-conserved spacers of 12 or 23 nucleotides.  Under physiologic conditions, V(D)J recombination follows the &quot;12/23 rule&quot; to assemble functional antigen-receptor genes, i.e., cleavage and recombination occur only between RS with dissimilar spacer types.  Functional, cryptic RS (cRS) have been identified in VH gene segments; these VH cRS were hypothesized to facilitate self-tolerance by mediating VH -&gt; VHDJH replacements.  At the Igkappa locus, however, secondary, de novo rearrangements can delete autoreactive VkappaJkappa joins.  Thus, under the hypothesis that V-embedded cRS are conserved to facilitate self-tolerance by mediating V-replacement rearrangements, there would be little selection for Vkappa cRS.  Recent studies have demonstrated that VH cRS cleavage is only modestly more efficient than V(D)J recombination in violation of the 12/23 rule and first occurs in pro-B cells unable to interact with exogenous antigens.  These results are inconsistent with a model of cRS cleavage during autoreactivity-induced VH gene replacement.
Results:
To test the hypothesis that cRS are absent from Vkappa gene segments, a corollary of the hypothesis that the need for tolerizing VH replacements is responsible for the selection pressure to maintain VH cRS, we searched for cRS in mouse Vkappa gene segments using a statistical model of RS.  Scans of 135 mouse Vkappa gene segments revealed highly conserved cRS that were shown to be cleaved in the 103/BCL2 cell line and mouse bone marrow B cells.  Analogous to results for VH cRS, we find that Vkappa cRS are conserved at multiple locations in Vkappa gene segments and are cleaved in pre-B cells.
Conclusions:
Our results, together with those for VH cRS, support a model of cRS cleavage in which cleavage is independent of BCR-specificity.  Our results are inconsistent with the hypothesis that cRS are conserved solely to support receptor editing.  The extent to which these sequences are conserved, and their pattern of conservation, suggest that they may serve an as yet unidentified purpose.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/37</link>
                <dc:creator>Anne Lieberman</dc:creator>
                <dc:creator>Masayuki Kuraoka</dc:creator>
                <dc:creator>Marco Davila</dc:creator>
                <dc:creator>Garnett Kelsoe</dc:creator>
                <dc:creator>Lindsay Cowell</dc:creator>
                <dc:source>BMC Immunology 2009, 10:37</dc:source>
        <dc:date>2009-06-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-37</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2009-06-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/36">
        <title>The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NF-kappaB and MAPK/AP-1 pathways in an in vitro model of Candida esophagitis</title>
        <description>Background:
Candida albicans resides on epithelial surfaces as part of the physiological microflora. However, under certain conditions it may cause life-threatening infections like Candida sepsis. Human &#946;-defensins (hBDs) are critical components of host defense at mucosal surfaces and we have recently shown that hBD-2 and hBD-3 are upregulated in Candida esophagitis. We therefore studied the role of Candidate signalling pathways in order to understand the mechanisms involved in regulation of hBD-expression by C. albicans. We used the esophageal cell line OE21 and analysed the role of paracrine signals from polymorphonuclear leukocytes (PMN) in an in vitro model of esophageal candidiasis.
Results:
Supernatants of C. albicans or indirect coculture with C. albicans induces upregulation of hBD-2 and hBD-3 expression. PMNs strongly amplifies C. albicans-mediated induction of hBDs. By EMSA we demonstrate that C. albicans activates NF-&#954;B and AP-1 in OE21 cells. Inhibition of these pathways revealed that hBD-2 expression is synergistically regulated by both NF-&#954;B and AP-1. In contrast hBD-3 expression is independent of NF-&#954;B and relies solely on an EGFR/MAPK/AP-1-dependent pathway.
Conclusion:
Our analysis of signal transduction events demonstrate a functional interaction of epithelial cells with PMNs in response to Candida infection involving divergent signalling events that differentially govern hBD-2 and hBD-3 expression.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/36</link>
                <dc:creator>Nadine Steubesand</dc:creator>
                <dc:creator>Karlheinz Kiehne</dc:creator>
                <dc:creator>Gabriele Brunke</dc:creator>
                <dc:creator>Rene Pahl</dc:creator>
                <dc:creator>Karina Reiss</dc:creator>
                <dc:creator>Karl-Heinz Herzig</dc:creator>
                <dc:creator>Sabine Schubert</dc:creator>
                <dc:creator>Stefan Schreiber</dc:creator>
                <dc:creator>Ulrich Folsch</dc:creator>
                <dc:creator>Philip Rosenstiel</dc:creator>
                <dc:creator>Alexander Arlt</dc:creator>
                <dc:source>BMC Immunology 2009, 10:36</dc:source>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-36</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2009-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/35">
        <title>Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells</title>
        <description>Background:
The SARS outbreak in 2003 provides a unique opportunity for the study of human responses to a novel virus. We have previously reported that dendritic cells (DCs) might be involved in the immune escape mechanisms for SARS-CoV. In this study, we focussed on the gene expression of toll-like receptors (TLRs), chemokine receptors (CCRs) and death receptor ligands in SARS-CoV infected DCs. We also compared adult and cord blood (CB) DCs to find a possible explanation for the age-dependent severity of SARS.
Results:
Our results demonstrates that SARS-CoV did not modulate TLR-1 to TLR-10 gene expression but significantly induced the expression of CCR-1, CCR-3, and CCR-5. There was also strong induction of TNF-related apoptosis-inducing ligand (TRAIL), but not Fas ligand gene expression in SARS-CoV infected DCs. Interestingly, the expressions of most genes studied were higher in CB DCs than adult DCs.
Conclusion:
The upregulation of chemokines and CCRs may facilitate DC migration from the infection site to the lymph nodes, whereas the increase of TRAIL may induce lymphocyte apoptosis. These findings may explain the increased lung infiltrations and lymphoid depletion in SARS patients. Further explorations of the biological significance of these findings are warranted.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/35</link>
                <dc:creator>Helen Law</dc:creator>
                <dc:creator>Chung Yan Cheung</dc:creator>
                <dc:creator>Sin Fun Sia</dc:creator>
                <dc:creator>Yuk On Chan</dc:creator>
                <dc:creator>Js Peiris</dc:creator>
                <dc:creator>Yu Lung Lau</dc:creator>
                <dc:source>BMC Immunology 2009, 10:35</dc:source>
        <dc:date>2009-06-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-35</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2009-06-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/34">
        <title>Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients</title>
        <description>Background:
As a cellular membrane triggering receptor, CD226 is involved in the NK cell- or CTL-mediated lysis of tumor cells of different origin, including freshly isolated tumor cells and tumor cell lines. Here, we evaluated soluble CD226 (sCD226) levels in sera, and membrane CD226 (mCD226) expression on peripheral blood mononuclear cells (PBMC) from cancer patients as well as normal subjects, and demonstrated the possible function and origin of the altered sCD226, which may provide useful information for understanding the mechanisms of tumor escape and for immunodiagnosis and immunotherapy.
Results:
Soluble CD226 levels in serum samples from cancer patients were significantly higher than those in healthy individuals (P &lt; 0.001), while cancer patients exhibited lower PBMC mCD226 expression than healthy individuals (P &lt; 0.001). CD226-Fc fusion protein could significantly inhibit the cytotoxicity of NK cells against K562 cells in a dose-dependent manner. Furthermore, three kinds of protease inhibitors could notably increase mCD226 expression on PMA-stimulated PBMCs and Jurkat cells with a decrease in the sCD226 level in the cell culture supernatant.
Conclusion:
These findings suggest that sCD226 might be shed from cell membranes by certain proteases, and, further, sCD226 may be used as a predictor for monitoring cancer, and more important, a possible immunotherapy target, which may be useful in clinical application.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/34</link>
                <dc:creator>Zhuwei Xu</dc:creator>
                <dc:creator>Tao Zhang</dc:creator>
                <dc:creator>Ran Zhuang</dc:creator>
                <dc:creator>Yun Zhang</dc:creator>
                <dc:creator>Wei Jia</dc:creator>
                <dc:creator>Chaojun Song</dc:creator>
                <dc:creator>Kun Yang</dc:creator>
                <dc:creator>Angang Yang</dc:creator>
                <dc:creator>Boquan Jin</dc:creator>
                <dc:source>BMC Immunology 2009, 10:34</dc:source>
        <dc:date>2009-06-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-34</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2009-06-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/33">
        <title>Bone marrow cell derived arginase I is the major source of allergen-induced lung arginase but is not required for airway hyperresponsiveness, remodeling and lung inflammatory responses in mice</title>
        <description>Background:
Arginase is significantly upregulated in the lungs in murine models of asthma, as well as in human asthma, but its role in allergic airway inflammation has not been fully elucidated in mice.
Results:
In order to test the hypothesis that arginase has a role in allergic airway inflammation we generated arginase I-deficient bone marrow (BM) chimeric mice. Following transfer of arginase I-deficient BM into irradiated recipient mice, arginase I expression was not required for hematopoietic reconstitution and baseline immunity. Arginase I deficiency in bone marrow-derived cells decreased allergen-induced lung arginase by 85.8 &#177; 5.6%. In contrast, arginase II-deficient mice had increased lung arginase activity following allergen challenge to a similar level to wild type mice. BM-derived arginase I was not required for allergen-elicited sensitization, recruitment of inflammatory cells in the lung, and proliferation of cells. Furthermore, allergen-induced airway hyperresponsiveness and collagen deposition were similar in arginase-deficient and wild type mice. Additionally, arginase II-deficient mice respond similarly to their control wild type mice with allergen-induced inflammation, airway hyperresponsiveness, proliferation and collagen deposition.
Conclusion:
Bone marrow cell derived arginase I is the predominant source of allergen-induced lung arginase but is not required for allergen-induced inflammation, airway hyperresponsiveness or collagen deposition.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/33</link>
                <dc:creator>Kathryn Niese</dc:creator>
                <dc:creator>Ann Collier</dc:creator>
                <dc:creator>Amanda Hajek</dc:creator>
                <dc:creator>Stephen Cederbaum</dc:creator>
                <dc:creator>William O'Brien</dc:creator>
                <dc:creator>Marsha Wills-Karp</dc:creator>
                <dc:creator>Marc Rothenberg</dc:creator>
                <dc:creator>Nives Zimmermann</dc:creator>
                <dc:source>BMC Immunology 2009, 10:33</dc:source>
        <dc:date>2009-06-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-33</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2009-06-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/32">
        <title>Different levels of humoral immunoreactivity to different wheat cultivars gliadin are present in patients with celiac disease and in patients with multiple myeloma.</title>
        <description>Background:
Immunity to food antigens (gliadin, cow&apos;s milk proteins) is in the centre of the attention of modern medicine focused on the prevention of diseases, prevention which is based on the use of appropriate restriction diet. Detection of the enhanced levels of the immune reactions to antigen(s) present in food is from this point of view of great importance because there are reports that some of health disturbances, like celiac disease (CD) and some premalignant conditions, like monoclonal gammopathy of undetermined significance (MGUS), were vanished after the appropriate restriction diets.It is well known that gliadin is toxic to small bowel mucosa of relatively small population of genetically predisposed individuals, who under this toxic action develop celiac disease (CD). As the quantity of immunogenic gliadin could vary between different wheat species, the first aim of this work was to determine the percentage of immunogenic gliadin in ten bread wheat cultivars and in three commercially grown durum wheat cultivars. The second part of the study was initiated by results of previous publication, reporting that sera of some of multiple myeloma (MM) patients showed the presence of elevated levels of anti-gliadin IgA, without the enhanced levels of anti-gliadin IgG antibodies, determined with commercial ELISA test. It was designed to assess is it possible to reveal is there any hidden, especially anti-gliadin IgG immunoreactivity, in serum of mentioned group of patients. For this purpose we tested MM patients sera, as well as celiac disease (CD) patients sera for the immunoreaction with the native gliadin isolated from wheat species used for bread and pasta making in corresponding geographic region.
Results:
Gliadin was isolated from wheat flour by two step 60% ehanolic extraction. Its content was determined by commercial R5 Mendez Elisa using PWG gliadin as the standard. Results obtained showed that immunogenic gliadin content varies between 50.4 and 65.4 mg/g in bread wheat cultivars and between 20 and 25.6 mg/g in durum wheat cultivars.Anti-gliadin IgA and IgG immunoreactivity of patients&apos; sera in (IU/ml) was firstly determined by commercial diagnostic Binding Site ELISA test, and then additionally by non-commercial ELISA tests, using standardized ethanol wheat extracts -gliadin as the antigen.In both patients groups IgA immunoreactivity to gliadin from different cultivars was almost homogenous and in correlation with results from commercial test (except for one patient with IgA(&#955;) myeloma, they were more then five times higher). But, results for IgG immunoreactivity were more frequently inhomogeneous, and especially for few MM patients, they were more then five times higher and did not correlate with results obtained using Binding Site test.
Conclusion:
Results obtained showed different content of immunogenic gliadin epitopes in various species of wheat.They also point for new effort to elucidate is there a need to develop new standard antigen, the representative mixture of gliadin isolated from local wheat species used for bread production in corresponding geographic region for ELISA diagnostic tests.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/32</link>
                <dc:creator>Aleksandra Konic-Ristic</dc:creator>
                <dc:creator>Dejan Dodig</dc:creator>
                <dc:creator>Radmilo Krstic</dc:creator>
                <dc:creator>Svetislav Jelic</dc:creator>
                <dc:creator>Ivan Stankovic</dc:creator>
                <dc:creator>Aleksandra Ninkovic</dc:creator>
                <dc:creator>Jelena Radic</dc:creator>
                <dc:creator>Irina Besu</dc:creator>
                <dc:creator>Branka Bonaci-Nikolic</dc:creator>
                <dc:creator>Njegica Jojic</dc:creator>
                <dc:creator>Milica Djordjevic</dc:creator>
                <dc:creator>Dragan Popovic</dc:creator>
                <dc:creator>Zorica Juranic</dc:creator>
                <dc:source>BMC Immunology 2009, 10:32</dc:source>
        <dc:date>2009-05-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-32</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2009-05-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/31">
        <title>High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area</title>
        <description>Background:
An accurate test for Mycobacterium tuberculosis infection is urgently needed in immunosuppressed populations. The aim of this study was to investigate the diagnostic power of enzyme-linked immunospot (ELISPOT)-based IFN-&#947; release assay in detecting active and latent tuberculosis in HIV-infected population in bacillus Calmette-Guerin (BCG)-vaccinated area. A total of 100 HIV-infected individuals including 32 active tuberculosis patients were recruited. An ELISPOT-based IFN-&#947; release assay, T-SPOT.TB, was used to evaluate the M. tuberculosis ESAT-6 and CFP-10 specific IFN-&#947; response. Tuberculin skin test (TST) was performed for all recruited subjects.
Results:
The subjects were divided into group HIV+ATB (HIV-infected individuals with active tuberculosis, n = 32), group HIV+LTB (HIV-infected individuals with positive results of T-SPOT.TB assay, n = 46) and group HIV only (HIV-infected individuals with negative results of T-SPOT.TB assay and without evidence of tuberculosis infection, n = 22). In group HIV+ATB and HIV+LTB, T-SPOT.TB positive rate in subjects with TST &lt;5 mm were 50% (16/32) and 41.3% (19/46), respectively. Individuals in group HIV+ATB and HIV+LTB with CD4+ T cells &lt;500/&#956;l, T-SPOT.TB showed a higher sensitivity than TST (64.5% vs. 22.6% and 62.2% vs. 29.7%, respectively, both P &lt; 0.0001). In addition, the sensitivity of T-SPOT.TB assay in group HIV+ATB increased to &gt;85% in patients with TB treatment for less than 1 month and CD4+ T cells &#8805;200/&#956;l, while for patients treated for more than 3 months and CD4+ T cells &lt;200/&#956;l, the sensitivity was decreased to only 33.3%. Furthermore, the results could be generated by T-SPOT.TB assay within 24 hours, which was more rapid than TST with 48&#8211;72 hours.
Conclusion:
ELISPOT-based IFN-&#947; release assay is more sensitive and rapid for the diagnosis of TB infection in Chinese HIV-infected individuals with history of BCG vaccination, and could be an effective tool for guiding preventive treatment with isoniazid in latently infected people and for TB control in China.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/31</link>
                <dc:creator>Weimin Jiang</dc:creator>
                <dc:creator>Lingyun Shao</dc:creator>
                <dc:creator>Ying Zhang</dc:creator>
                <dc:creator>Shu Zhang</dc:creator>
                <dc:creator>Chengyan Meng</dc:creator>
                <dc:creator>Yunya Xu</dc:creator>
                <dc:creator>Lingli Huang</dc:creator>
                <dc:creator>Yun Wang</dc:creator>
                <dc:creator>Ying Wang</dc:creator>
                <dc:creator>Xinhua Weng</dc:creator>
                <dc:creator>Wenhong Zhang</dc:creator>
                <dc:source>BMC Immunology 2009, 10:31</dc:source>
        <dc:date>2009-05-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-31</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>31</prism:startingPage>
        <prism:publicationDate>2009-05-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/30">
        <title>Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red blood cells</title>
        <description>Background:
Human tonsils are a rich source of B lymphocytes exhibiting a variety of phenotypes and activation states. Existing methods of purification are time consuming or costly. The aim of the present study was to optimize conditions to isolate large numbers of highly purified primary B lymphocytes from tonsils in a short and cost-effective single step, using a commercially available reagent designed for purifying cells from whole blood (RosetteSep). This technique relies on the presence of the large excess of red blood cells in whole blood for the formation of immunorosettes, whereas single cell suspensions from tonsils contain relatively few red blood cells.
Results:
B cell enrichment from tonsils was achieved using RosetteSep with no modification to the whole blood procedure; however, the degree of purity depended on the extent of red blood cell contamination of the starting tonsil cell suspension. Addition of a 50-fold excess of allogeneic human red blood cells, but not sheep red blood cells, reproducibly resulted in high levels of purity. Depletion of mononuclear cells from the donor red blood cells eliminated potential contamination with allogeneic B cells.
Conclusion:
RosetteSep reagent can be used in combination with allogeneic human red blood cells to reproducibly isolate tonsil B lymphocytes to high levels of purity with no change in phenotype or loss of cells. This method provides considerable time and cost savings compared to other methods.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/30</link>
                <dc:creator>Jonathan Zuccolo</dc:creator>
                <dc:creator>Tammy Unruh</dc:creator>
                <dc:creator>Julie Deans</dc:creator>
                <dc:source>BMC Immunology 2009, 10:30</dc:source>
        <dc:date>2009-05-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-30</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>30</prism:startingPage>
        <prism:publicationDate>2009-05-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/29">
        <title>T cells cooperate with palmitic acid in induction of beta cell apoptosis</title>
        <description>Background:
Diabetes is characterized by progressive failure of insulin producing beta cells. It is well known that both saturated fatty acids and various products of immune cells can contribute to the reduction of beta cell viability and functionality during diabetes pathogenesis. However, their joint action on beta cells has not been investigated, so far. Therefore, we explored the possibility that leukocytes and saturated fatty acids cooperate in beta cell destruction.
Results:
Rat pancreatic islets or insulinoma cells (RIN) were co-cultivated with concanavalin A (ConA)-stimulated rat lymph node cells (LNC), or they were treated with cell-free supernatants (Sn) obtained from ConA-stimulated spleen cells or from activated CD3+ cells, in the absence or presence of palmitic acid (PA). ConA-stimulated LNC or Sn and PA cooperated in inducing caspase-3-dependent RIN cell apoptosis. The observed effect of PA and Sn on RIN cell viability was mediated by p38 mitogen-activated protein kinase (MAPK)-signaling and was achieved through auto-destructive nitric oxide (NO) production. The cooperative effect of Sn was mimicked with the combination of interleukin-1&#946;, interleukin-2, interleukin-6, interleukin-17, interferon-&#947; and tumor necrosis factor-&#945;.
Conclusion:
These results imply that stimulated T cells produce cytokines that cooperate with saturated free fatty acids in beta cell destruction during diabetes pathogenesis.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/29</link>
                <dc:creator>Tamara Cvjeticanin</dc:creator>
                <dc:creator>Ivana Stojanovic</dc:creator>
                <dc:creator>Gordana Timotijevic</dc:creator>
                <dc:creator>Stanislava Stosic-Grujicic</dc:creator>
                <dc:creator>Djordje Miljkovic</dc:creator>
                <dc:source>BMC Immunology 2009, 10:29</dc:source>
        <dc:date>2009-05-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-29</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>29</prism:startingPage>
        <prism:publicationDate>2009-05-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/28">
        <title>A kinase dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice</title>
        <description>Background:
The mammalian target of rapamycin protein (mTOR) is an evolutionarily conserved kinase that regulates protein synthesis, cell cycle progression and proliferation in response to various environmental cues. As a critical downstream mediator of PI3K signaling, mTOR is important for lymphocyte development and function of mature T and B-cells. Most studies of mTOR in immune responses have relied on the use of pharmacological inhibitors, such as rapamycin. Rapamycin-FKBP12 complex exerts its immunosuppressive and anti-proliferative effect by binding outside the kinase domain of mTOR, and subsequently inhibiting downstream mTOR signaling.
Results:
To determine the requirement for mTOR kinase activity in the immune system function, we generated knock-in mice carrying a mutation (D2338) in the catalytic domain of mTOR. While homozygous mTOR kd/kd embryos died before embryonic day 6.5, heterozygous mTOR+/kd mice appeared entirely normal and are fertile. mTOR +/kd mice exhibited normal T and B cell development and unaltered proliferative responses of splenocytes to IL-2 and TCR/CD28. In addition, heterozygousity for the mTOR kinase-dead allele did not sensitize T cells to rapamycin in a CD3-mediated proliferation assay. Unexpectedly, mTOR kinase activity towards its substrate 4E-BP1 was not decreased in hearts and livers from heterozygous animals.
Conclusion:
Altogether, our findings indicate that mTOR kinase activity is indispensable for the early development of mouse embryos. Moreover, a single wild type mTOR allele is sufficient to maintain normal postnatal growth and lymphocyte development and proliferation.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/28</link>
                <dc:creator>Boris Shor</dc:creator>
                <dc:creator>Druie Cavender</dc:creator>
                <dc:creator>Crafford Harris</dc:creator>
                <dc:source>BMC Immunology 2009, 10:28</dc:source>
        <dc:date>2009-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-28</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>28</prism:startingPage>
        <prism:publicationDate>2009-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
